Seeking Alpha
20 Aug 2026, 05:19 UTC · 2h ago
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
20 Aug 2026, 05:19 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Haduvio has demonstrated positive Phase II data for both Idiopathic Pulmonary Fibrosis (IPF) and Refractory Chronic Cough (RCC). — Positive Phase II data significantly derisks clinical development and increases the probability of regulatory approval.
+0.80Trevi Therapeutics is currently conducting pivotal trials for Haduvio. — Moving into pivotal trials is the final major clinical hurdle before potential commercialization.
+0.60The company maintains robust liquidity to support its transition to a specialty pharma platform. — Strong cash positions reduce the immediate risk of dilutive financing rounds during expensive late-stage trials.
+0.40Continue reading
6 related stories
Search tags
Trevi plans to expand Haduvio's application into non-IPF Interstitial Lung Disease (ILD) and refractory chronic cough. — Expanding the Total Addressable Market (TAM) increases the long-term valuation potential of the drug.
Which stocks this story touches
Positive Phase II data, ongoing pivotal trials, and robust liquidity support its strategic transition to a specialty pharma platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
17h ago
